Home > Arthrosi


Company Information

Arthrosi focuses on therapeutic development to treat the root cause of hyperuricemia and gout The AR882(for Hyperuricemia and gout) is on the Phase 1 Australia, Phase 1 US and Phase 2 New Zealand. The core team has rich successful experience in gout project R&D, clinical trials, FDA approval and product docking with American pharmaceutical companies.